Cost-effectiveness analysis of HPV vaccination of men who have sex with men in Germany
Vaccination of MSM up to 26 and 45 years of age can profoundly accelerate beneficial public health outcomes while reducing the economic burden of HPV-related cancers and anogenital warts in a cost-effective way compared to vaccinating adolescent boys only.
Authors
- Cody Palmer (ORCID: https://orcid.org/0000-0002-9060-5999)
- Miriam Reuschenbach (ORCID: https://orcid.org/0000-0003-4268-6250)
- Agnes Luzak
- Regine Wölle
- Jens Peter Klußmann (ORCID: https://orcid.org/0000-0002-8223-7954)
- Cornelia Wähner
- Alexander Kreuter (ORCID: https://orcid.org/0000-0003-2275-499X)
- Julian Witte (ORCID: https://orcid.org/0000-0003-2075-323X)
Institutions
- University of Cologne (DE)
- Bielefeld University (DE)
- MSD (Germany) (DE)
- HELIOS St. Elisabeth Klinik Oberhausen (DE)
Publication Details
- Journal
- Infection
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1007/s15010-025-02567-z
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35